Truveta’s Post

#Ovariancancer is exceptionally difficult to diagnose, and in urgent need of breakthrough research. Now, Truveta offers the most complete, longitudinal #cancercaredata across the #continuumofcare, including 21M encounters, 82M labs, and 1.1M imaging studies across 106K #ovarian #cancerpatients. With this wealth of data, #researchers can advance #diagnostics, support new #therapydevelopment, and improve #patientoutcomes. Learn more about our ovarian cancer data available for research in Truveta Data below 👇: https://tr.vet/3A35SDg 💡🧬

As we recognize Breast Cancer Awareness Month, it’s vital to reflect on both our progress and the challenges we still face. In 2024, an estimated 310,720 new cases of invasive breast cancer will be diagnosed in the U.S. alone, with about 42,250 women expected to die from the disease. While advances in early detection—particularly in hormone receptor-positive breast cancer—have improved survival rates, we must remain focused on the continued rise in diagnoses among younger women, with incidence increasing by 1.4% annually in women under 50. In recent years, breast cancer treatment has shifted toward targeted therapies aimed at improving outcomes while reducing the physical toll on patients. These therapies focus on specific molecular pathways that drive cancer growth, offering more precise treatments with fewer side effects. The ongoing development of these approaches holds promise for not only extending survival but also improving patients’ quality of life, allowing them to navigate treatment with greater resilience and strength. I feel privileged to be part of a community of researchers, clinicians, and advocates all dedicated to improving care for women everywhere. Together, we are moving closer to a future where every woman diagnosed with breast cancer has access to better, more personalized treatments that not only save lives but also support recovery and well-being. #BreastCancerAwareness #BreastCancerResearch #TargetedTherapies #WomensHealth #InnovatingForChange #BreastCancerAwarenessMonth #BreastCancer

With over 2.3 million new breast cancer cases expected this year and 310,000 in the U.S. alone, progress in treatment is more critical than ever. Thanks to advances in research, breast cancer mortality has decreased by an estimated 44%.  These achievements show how far we’ve come, but they also remind us of the work still ahead. New approaches, such as CDK4/6 inhibitors like Kisqali, have revolutionized treatment for HR+/HER2- breast cancer, offering more precise and targeted options for patients. The recent FDA approval of Kisqali for early-stage breast cancer is a significant milestone, showing how innovations in targeted therapies can bring hope and improved outcomes. However, many patients—particularly those with early-stage or high-risk disease—still face limited therapeutic choices. As research continues, the future of breast cancer treatment lies in developing more precise, molecularly targeted therapies that not only extend survival but also minimize side effects, improving patients' quality of life. As we’ve seen with recent breakthroughs, the promise of innovation is real, and we are committed to advancing treatments that one day may also make a difference for all breast cancer patients. This month, we reflect on the progress made and renew our focus on driving forward the next generation of treatments. #BreastCancerAwareness #BreastCancerResearch #WomensHealth #TargetedTherapies #InnovatingForPatients #BreastCancerAwarenessMonth

According to the American Cancer Society, #ColorectalCancer (CRC) is the third most common cancer diagnosed in the U.S. and the third leading cause of cancer-related deaths. Yet an estimated 60% of CRC deaths are preventable for those who follow colorectal cancer screening guidelines. This has organizations seeking a direct, cost-effective solution that drives screenings and quality patient care among members. A #GapsInCare program is an end-to-end solution that combines convenient at-home access to a fit test with quality reporting and patient engagement. The goal is to help improve quality measures performance, lower costs and improve access to care. Read more for considerations when implementing your program:

Every 14 seconds, somewhere in the world, a woman is diagnosed with breast cancer… Making it the second most common cancer in the world, according to the Breast Cancer Research Foundation. Early detection literally saves lives. This makes the validity of having an annual Breast Cancer awareness month, held in October, extremely obvious. At LOGEX, we also see Breast Cancer Awareness Month as an important time to reflect on the challenges and advancements in the treatment of patients with breast cancer. Our focus is on leveraging real-world data and analytics. Through collaborations with healthcare providers, researchers, life science companies and patient organisations, we aim to increase the understanding of how care is being provided internationally and how optimisation is possible in order to achieve more positive outcomes at a faster pace for patients. Thu ultimate goal is to reduce the impact of breast cancer on patients and their families. Two examples of our work in this field: 1- Should breast cancer patients suffer from heartburn to not temper with the effectiveness of their cancer treatment, as is suggested by literature? Our real-world data research implies that the answer is ‘no’: Proton pump inhibitors help reduce heartburn and their use does not show a negative effect on the effectiveness of the cancer treatment: https://lnkd.in/eH6mZd5k. 2- The outcomes of the treatment of breast cancer varies quite significantly, even when looking at just European countries. There are important knowledge gaps in our understanding of how these variations can be explained. LOGEX worked with researchers and hospitals across Europe to gather and analyse real-world data on care paths in different countries, leading to some highly relevant insights and best practices https://lnkd.in/eD-MkV4M. Curious to learn more about how we try to turn data into better healthcare? Visit logex.com. Esther Dronkers,Esmée van Geffen,Naomi de Kruif,Nicole Kerklaan,Femke Oldenziel,Jan van der Eijk,Pieter Krop,Shannen van Duijn,Zelda Odé,Lia Lapian #LOGEX #BreastCancerAwareness #BCAM2024 #EarlyDetectionSavesLives #BreastCancerResearch #FightBreastCancer #HopeForACure #StrongerTogether #RealWorldData #DataForGood #HealthcareInnovation #PatientCare #LOGEXCares #SupportTheCause #PinkRibbonMonth

A recent JAMA study featured in The Washington Post observed a 58% decline in breast cancer mortality since 1975, with the most significant improvements seen over the last 10 years. This is truly a remarkable account of the power of research that BCRF is committed to. While research is typically, and necessarily, incremental in nature, over the last decade we’ve been progressing by leaps and bounds thanks to advancements in technology and our understanding of the disease. But we still have work to do to improve outcomes for all. We remain committed to ensuring equitable progress. https://wapo.st/432ZLJA

🩺 Cancer Clinical Trial Spotlight 🔬 Stomach cancer is the fourth leading cause of cancer deaths worldwide and one that usually isn’t detected until it is in advanced stages. Once the cancer cells have spread into the abdominal cavity and lining, or peritoneum — a condition called gastric carcinomatosis — the survival rate is little more than six months. This is particularly concerning because the incidence of stomach cancer is on the rise in U.S. adults under 50, especially among Hispanics. To improve options for these patients, UCI Health surgical oncologist Dr. Maheswari Senthil has teamed up with UCI Health medical oncologist Dr. Farshid Dayyani, a leading expert in gastrointestinal malignancies and medical director of the cancer center’s Stern Center for Cancer Clinical Trials and Research. Together, they have launched STOPGAP, an innovative phase 2 clinical trial that takes a three-pronged approach to treating gastric carcinomatosis. STOPGAP is the only U.S. clinical trial to use all three treatment modes for advanced gastric and gastroesophageal adenocarcinomas. The goal is to demonstrate that this combination therapy is safe and improves patient survival rates. It is supported in part by seed money from the UCI Anti-Cancer Challenge. Learn more about this trial at the 2024 Kickoff on Thursday, May 30. RSVP today: https://lnkd.in/gg6jfBDj #stomachcancer #cancerresearch #communitysupport #clinicaltrials

🎗️ Fighting Triple Negative Breast Cancer with Innovation 🎗️ October is Breast Cancer Awareness Month, and it’s time to shed light on one of the most challenging types to treat: Triple Negative Breast Cancer (TNBC). Traditional treatments for TNBC have shown limited success, and even newer targeted therapies haven’t provided significant breakthroughs for many patients. But there’s hope on the horizon, and it’s called Pulse Electric Field Therapy. 💡 Recent Research Highlights: ✅ Induced Cell Death: This therapy increases apoptosis (programmed cell death) and necrosis in both lab (in vitro) and animal models (in vivo). ✅ Tumor Reduction: Studies show a significant reduction in tumor size using Pulse Electric Field Therapy for TNBC. ✅ Immune Activation: The therapy boosts chemokine CXCL9 production, increasing immune infiltration into the tumor microenvironment. This helps cytotoxic T lymphocytes effectively target and destroy cancer cells. What makes Pulse Electric Field Therapy so unique is that it activates the immune system locally and trains it to fight cancer cells. It then sends these activated immune responses throughout the body via the abscopal effect. It’s cutting-edge, low-invasive, and represents the future of cancer treatment—available today at the Williams Cancer Institute. 🔬 If you or someone you know is battling breast cancer, schedule a free consultation with us through the link in our bio. Let’s explore your options together and take control of your journey towards healing. 💪 Supporting evidence in the comments ⬇️⬇️ #BreastCancerAwareness #TripleNegativeBreastCancer #TNBC #PulseElectricFieldTherapy #WilliamsCancerInstitute #InnovativeTherapy #CancerTreatment #BreastCancerResearch #ImmuneSystem #CancerFighter #HopeForHealing #IntegrativeOncology #CancerBreakthrough #CuttingEdgeMedicine #FutureOfHealthcare #HealingJourney

🩺📉 Exploring the effects of the early phase of the COVID-19 pandemic on newly diagnosed breast cancer cases, this study focuses on Commission on Cancer (CoC)-accredited facilities in the United States. By examining the relationship between pandemic onset and breast cancer diagnoses, the research aims to provide insights into healthcare dynamics during crisis periods. Understanding these impacts is crucial for optimizing healthcare strategies and ensuring timely detection and treatment of breast cancer. #BreastCancer #COVID19 #HealthcareResearch 🩺🔬

New Update from NHS England's Cancer Programme. The latest report from NHS England on cancer care progress has just been released. Here are some key points that are important to us at ALK Positive Lung Cancer UK: → Early Diagnosis: The NHS has met its goal of diagnosing or ruling out cancer within 28 days for 75% of patients. This is a significant step in providing care quickly. → Lung Health Checks: There are plans to expand the Targeted Lung Health Checks into a national screening program by 2028-29. This could greatly improve early detection of lung cancer. → Diagnostic Technologies: New technologies like ctDNA testing and the Cancer Vaccines Launch Pad are improving how we diagnose and treat cancer, allowing for more tailored care. → Improvement in Diagnosis Rates: For the first time in ten years, there's been a notable increase in the rate of early cancer diagnoses, which is key for better treatment outcomes. These developments offer hope and improved chances for those affected by cancer. Read the report https://lnkd.in/eGz-GeBY #CancerProgress #CancerCare #LungCancer #EarlyDiagnosis